InvestorsHub Logo
Followers 6
Posts 923
Boards Moderated 0
Alias Born 09/28/2012

Re: None

Monday, 02/25/2019 3:47:30 PM

Monday, February 25, 2019 3:47:30 PM

Post# of 9135
This was probably the reason for the spike in volume and price today.

"Phase III COLUMBA study comparing the subcutaneous formulation of daratumumab to the intravenous formulation in patients with relapsed or refractory multiple myeloma met both co-primary endpoints
Results show that daratumumab administered subcutaneously was non-inferior in efficacy and pharmacokinetics as compared to daratumumab administered intravenously
Data will be discussed with health authorities to prepare for regulatory filings in support of bringing convenience of subcutaneous daratumumab option to patients"

https://globenewswire.com/news-release/2019/02/25/1741776/0/en/Genmab-Announces-Positive-Topline-Results-in-Phase-III-COLUMBA-Study-of-Subcutaneous-Daratumumab.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News